Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adimab, a US-based provider of fully human antibodies and bispecifics, has entered into a multi-target discovery and optimization collaboration with Sanofi.
Subscribe to our email newsletter
As part of the deal, Adimab will use its proprietary platform to produce therapeutic antibodies and bispecifics molecules against multiple targets, which will be developed and commercialized by Sanofi.
Adimab CEO and co-founder Tillman Gerngross said: "Adimab has recently emerged as a major player in the bispecifics discovery space. Our unique protein engineering capabilities allow us to rapidly build libraries around almost any bispecific construct.
"All leads are ‘filtered’ through Adimab’s genetically modified yeast strain leading to well-expressing and stable therapeutic leads that can readily be assessed for biological function.
"No other technology can create such a diverse panel of functional and developable leads in such a short time."
For each project, Sanofi will have the right to research antibodies and bispecifics generated during the collaboration for potential use as therapeutic products.
The deal will see Adimab receive an undisclosed upfront payment, research fees and technical milestones.
Additionally, for each target, Sanofi will have the option to exclusively license antibodies and bispecifics produced during the collaboration and if it exercises the option for a particular therapeutic lead, Adimab would receive license fees, clinical milestones and royalties on product sales.
Adimab Business Development vice-president Guy Van Meter said: "More and more companies are focused on bispecific approaches to go after intricate disease biology.
"Our capabilities have grown tremendously, and Adimab has added 18 new bispecific therapeutic programs in the past 12 months alone."